Elanco Animal Health has received U.S. Department of Agriculture approval for Befrena (tirnovetmab), an anti–IL-31 monoclonal antibody injection for the treatment of canine allergic and atopic dermatitis. According to the company, the product is intended for use in dogs of any age and is recommended at dosing intervals of six to eight weeks following treatment. Elanco expects to launch the product in the first half of 2026. The approval marks Elanco’s second dermatology-related product clearance in less than 18 months, following Zenrelia (ilunocitinib tablets), an oral JAK inhibitor indicated for itching and inflammation associated with canine skin allergies. Elanco noted that recent updates to the Zenrelia label removed a specific vaccine-related risk statement, while existing boxed warnings on vaccination timing remain in place. Elanco also cited findings from its “America’s Itchy Dogs Report,” which highlights the prevalence of itch-related skin conditions in dogs and delays in seeking veterinary care. For more information, visit the Elanco website.
